Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: A randomised phase II study

British Journal of Cancer

Volumn 104, Issue 4, 2011, Pages 613-619

  Petrioli, R ^a   Pascucci, A ^a   Conca, R ^a   Chiriaco G ^a   Francini, E ^a   Bargagli, G ^a   Fiaschi, A I ^a   Manganelli, A ^a   De Rubertis, G ^a   Barbanti, G ^a   Ponchietti, R ^a   Francini, G ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

bone metastases; castrate resistant; docetaxel; epirubicin; prostate cancer; prostate specific antigen

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BEVACIZUMAB; DOCETAXEL; EPIRUBICIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CHEMOTHERAPY INDUCED EMESIS; CONGESTIVE HEART FAILURE; CONSTIPATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EPIPHORA; EPISTAXIS; FATIGUE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORCHIECTOMY; PREDNISONE; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT FAILURE;

EID: 79951671971     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.5     Document Type: Article

References (27)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI 85: 365-376 (Pubitemid 23073154)
2. Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12: 1273-1279 (Pubitemid 32994757)
3. Brausi M, Jones WG, Fossa SD, de Mulder PH, Droz JP, Lentz MA, van Glabbeke M, Pawinski A (1995) High-dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC genitourinary group. Eur J Cancer 31A: 1622-1626
4. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59-69
5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for Phase II clinical trials in androgen independent prostate cancer: recommendations from the Prostate-specific Antigen Working Group. J Clin Oncol 17: 3461-3467 (Pubitemid 29517916)
6. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925-4935 (Pubitemid 46223998)
7. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH (2005) Is prostate-specific antigen a valid surrogate and point for survival in hormonally treated patients with metastatic prostate cancer? J Clin Oncol 23: 6139-6148
8. De Benedittis G, Massei R, Nobili R, Pieri A (1988) The Italian Pain Questionnaire. Pain 33: 53-62
9. Engels FK, Verweij J (2005) Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 41: 1117-1126 (Pubitemid 40725569)
10. Francini G, Petrioli R, Gonnelli S, Correale P, Pozzessere D, Marsili S, Montagnani A, Lucani B, Rossi S, Monaco R, Manganelli A, Salvestrini F, Fiaschi AI (2001) Urinary calcium excretion in the monitoring of bone metastases. Cancer 92: 1468-1474 (Pubitemid 32947831)
11. Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A, Mondillo S (1993) Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 67: 1430-1436 (Pubitemid 23172892)
12. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21: 1232-1237 (Pubitemid 46606398)
13. Heidenreich A, Pfister DA, Thüer R, Ther D, Epplen R, Firek P, Brehmer B (2010) Docetaxel rechallenge versus docetaxel/bevacizumab in castra-tion-resistant prostate cancer following first-line docetaxel. J Clin Oncol 28(Suppl): abstr e15006
14. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, Morris MJ, Kantoff PW, Monk III JP, Small EJ (2010) A randomized, double blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant (mCRPC): survival results of CALGB 90401. J Clin Oncol 28: 18s (Suppl): abstr LBA4511
15. McCormack A, Hunter-Smith D, Piotrowski ZH, Grant M, Kubik S, Kessel K (1992) Analgesic use in home hospice cancer patients. J Fam Pract 34: 160-164
16. Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1: 277-299
17. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 2070-2076
18. Osoba D, Rodrigues C, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 16: 139-144 (Pubitemid 28041591)
19. Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G (2008) The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev 34: 710-718
20. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G (2007) Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostrate cancer. Urology 69: 142-146 (Pubitemid 46161681)
21. Petrioli R, Pozzessere D, Messinese S, Sabatino M, Ceciarini F, Marsili S, Correale P, Fiaschi AI, Voltolini L, Gotti G, Francini G (2002) Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 87: 720-725 (Pubitemid 35178748)
22. Petrioli R, Pozzessere D, Messinese S, Sabatino M, Di Palma T, Marsili S, Correale P, Manganelli A, Salvestrini F, Francini G (2003) Weekly low-dose docetaxel in hormone-resistant advanced prostate cancer patients previously exposed to chemotherapy. Oncology 64: 300-305 (Pubitemid 36682940)
23. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520 (Pubitemid 39315318)
24. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381 (Pubitemid 16163075)
25. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512 (Pubitemid 39315317)
26. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764 (Pubitemid 26185452)
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SC (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-261